Advertisement
Australia markets close in 18 minutes

  • ALL ORDS

    7,837.10
    -100.40 (-1.26%)
     

  • ASX 200

    7,576.50
    -106.50 (-1.39%)
     

  • AUD/USD

    0.6541
    +0.0018 (+0.28%)
     

  • OIL

    83.94
    +0.37 (+0.44%)
     

  • GOLD

    2,346.50
    +4.00 (+0.17%)
     

  • Bitcoin AUD

    98,662.23
    +407.55 (+0.41%)
     

  • CMC Crypto 200

    1,389.20
    +6.63 (+0.48%)
     

  • AUD/EUR

    0.6097
    +0.0023 (+0.39%)
     

  • AUD/NZD

    1.0965
    +0.0008 (+0.07%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,679.36
    +394.82 (+2.28%)
     

  • NIKKEI 225

    38,004.26
    +375.78 (+1.00%)
     

Immuron CEO, Steven Lydeamore to present at AusBioInvest

Immuron Limited
·1-min read
Immuron Limited
Immuron Limited

MELBOURNE, Australia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases; is pleased to provide investors with a copy of the presentation slide deck to be showcased at AusBioInvest 2022 in Perth, Australia on October 27, 2022, by our Chief Executive Officer, Steven Lydeamore.

A copy of the presentation slide deck is available on the Company’s website.

https://www.immuron.com.au/corporate-presentations/

ADVERTISEMENT

This release has been authorised by the directors of Immuron Limited.

COMPANY CONTACT:

Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com

 

 

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

For more information visit: http://www.immuron.com